20:08:47 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



Aptose Biosciences Inc (3)
Symbol APS
Shares Issued 7,736,747
Close 2023-07-27 C$ 5.20
Market Cap C$ 40,231,084
Recent Sedar Documents

Aptose to release Q2 results, host call Aug. 10

2023-07-27 16:17 ET - News Release

Ms. Susan Pietropaolo reports

APTOSE TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS AND HOLD CONFERENCE CALL ON THURSDAY, AUGUST 10, 2023

Aptose Biosciences Inc. will release financial results for the second quarter ended June 30, 2023, on Thursday, Aug. 10, 2023, after the close of the market, and provide a corporate update.

Conference call and webcast

Date:  Thursday, Aug. 10, 2023

Time:  5 p.m. ET

An audio webcast will be available.

Analysts interested in participating in the question-and-answer session will preregister for the event to receive the dial-in numbers and a unique PIN, which are required to listen to the conference call. They also will have the option to take advantage of a call-me button, and the system will automatically dial out to connect to the Q&A session.

The audio webcast also will be available through a link on the investor relations section of Aptose's website. A replay of the webcast will be available on the company's website for 30 days.

The press release, the financial statements, and management's discussion and analysis for the quarter ended June 30, 2023, will be available on SEDAR and EDGAR.

About Aptose Biosciences Inc.

Aptose is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small-molecule cancer therapeutics pipeline includes products designed to provide single-agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the Aptivate international phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia; and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

© 2024 Canjex Publishing Ltd. All rights reserved.